Osteoprotegerin polyclonal, anti-human

Protein Family: Receptors and Channels, Cellular Antigens

Pathway and Disease: Signaling Molecules and Interaction, Development and Behavior

Description:
Osteoclastogenesis inhibitory factor (osteoprotegerin) acts as a decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Osteoprotegerin also acts as a decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Osteoprotegerin inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis depends on the local RANKL/osteoprotegerin ratio. Defects in osteoprotegerin are the cause of juvenile Paget disease (JPD). JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.

Alternate Names: Tumor necrosis factor receptor superfamily member 11B, Osteoprotegerin, Osteoclastogenesis inhibitory factor, TNFRSF11B, OCIF, OPG

Application Notes: E: 1:10,000-1:50,000; WB: 1:200-1:1,000; IHC: 1:50-1:200

Accession No.: O00300

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human osteoprotegerin.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4, 0.5% BSA with 0.09% sodium azide. Antibody was purified by immunogen affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.